iTeos Therapeutics, Inc. (NASDAQ:ITOS) Given Consensus Recommendation of “Hold” by Brokerages

iTeos Therapeutics, Inc. (NASDAQ:ITOS) has received a consensus rating of “Hold” from the seven ratings firms that are presently covering the firm, Marketbeat Ratings reports. Six investment analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $15.86.

Several research analysts have recently commented on ITOS shares. Raymond James Financial set a $12.00 price target on shares of iTeos Therapeutics in a report on Wednesday, May 14th. Wells Fargo & Company reaffirmed an “equal weight” rating and issued a $12.00 price target (down from $13.00) on shares of iTeos Therapeutics in a report on Wednesday, May 28th. HC Wainwright lowered shares of iTeos Therapeutics from a “buy” rating to a “neutral” rating in a report on Wednesday, May 14th. JPMorgan Chase & Co. lowered shares of iTeos Therapeutics from an “overweight” rating to a “neutral” rating and decreased their price target for the company from $15.00 to $8.00 in a report on Tuesday, May 13th. Finally, Wedbush lowered shares of iTeos Therapeutics from an “outperform” rating to a “neutral” rating and lifted their price target for the company from $10.00 to $12.00 in a report on Wednesday, May 28th.

iTeos Therapeutics Stock Performance

Shares of iTeos Therapeutics stock opened at $10.23 on Thursday. The firm has a market cap of $391.54 million, a PE ratio of -3.37 and a beta of 1.49. The firm’s 50-day simple moving average is $9.17 and its 200-day simple moving average is $7.79. iTeos Therapeutics has a 1 year low of $4.80 and a 1 year high of $18.13.

iTeos Therapeutics (NASDAQ:ITOS) last issued its earnings results on Monday, April 28th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.14. On average, equities analysts predict that iTeos Therapeutics will post -3.49 earnings per share for the current year.

Insider Buying and Selling

In related news, Director David Hallal sold 38,228 shares of the stock in a transaction dated Friday, June 6th. The shares were sold at an average price of $10.24, for a total value of $391,454.72. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Michel Detheux sold 43,883 shares of the stock in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $10.02, for a total transaction of $439,707.66. Following the completion of the sale, the chief executive officer directly owned 153,903 shares in the company, valued at approximately $1,542,108.06. This trade represents a 22.19% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,939,307 shares of company stock valued at $16,202,116 in the last quarter. Company insiders own 12.50% of the company’s stock.

Institutional Investors Weigh In On iTeos Therapeutics

Several institutional investors have recently bought and sold shares of the stock. RA Capital Management L.P. lifted its holdings in iTeos Therapeutics by 74.4% in the first quarter. RA Capital Management L.P. now owns 3,649,057 shares of the company’s stock worth $21,785,000 after purchasing an additional 1,556,798 shares during the period. BVF Inc. IL lifted its holdings in iTeos Therapeutics by 32.3% in the first quarter. BVF Inc. IL now owns 3,075,000 shares of the company’s stock worth $18,358,000 after purchasing an additional 750,000 shares during the period. JPMorgan Chase & Co. lifted its holdings in iTeos Therapeutics by 342.7% in the fourth quarter. JPMorgan Chase & Co. now owns 2,068,796 shares of the company’s stock worth $15,888,000 after purchasing an additional 1,601,477 shares during the period. 683 Capital Management LLC lifted its holdings in iTeos Therapeutics by 90.6% in the first quarter. 683 Capital Management LLC now owns 1,750,000 shares of the company’s stock worth $10,448,000 after purchasing an additional 831,883 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in iTeos Therapeutics by 15.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,210,080 shares of the company’s stock worth $9,293,000 after purchasing an additional 163,880 shares during the period. Institutional investors and hedge funds own 97.16% of the company’s stock.

About iTeos Therapeutics

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.